Article
Mutations close to functional motif IV in HSV-1 UL5 helicase that confer resistance to HSV helicase-primase inhibitors, variously affect virus growth rate and pathogenicity.
Antiviral research - 1 Oct 2008
Biswas Subhajit, Tiley Laurence S, Zimmermann Holger, Birkmann Alexander, Field Hugh J
Abstract excerpt
Herpes simplex virus (HSV) helicase-primase (HP) is the target for a novel class of antiviral compounds, the helicase-primase inhibitors (HPIs), e.g. BAY 57-1293. Although mutations in herpesviruses conferring resistance to nucleoside analogues are commonly associated with attenuation in vivo, to date, this is not necessarily true for HPIs. HPI-resistant HSV mutants selected in tissue culture are reported to be...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.